|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
|
US11306107B2
(en)
|
2016-02-25 |
2022-04-19 |
Amgen Inc. |
Compounds that inhibit MCL-1 protein
|
|
CN121974842A
(zh)
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
WO2018015526A1
(en)
|
2016-07-22 |
2018-01-25 |
Les Laboratoires Servier |
Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
|
|
JP6453507B2
(ja)
*
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１タンパク質を阻害する化合物
|
|
EP4717317A3
(en)
|
2017-06-20 |
2026-06-03 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
CR20200124A
(es)
*
|
2017-08-15 |
2020-09-28 |
Abbvie Inc |
Inhibidores macrocíclicos de mcl-1 y métodos de uso
|
|
MX2020001719A
(es)
*
|
2017-08-15 |
2020-11-06 |
Abbvie Inc |
Inhibidores macrocíclicos de mcl-1 y metodos de uso.
|
|
ES3036998T3
(en)
|
2017-08-18 |
2025-09-26 |
Amgen Inc |
Compounds that inhibit mcl-1 protein
|
|
MA50033A
(fr)
|
2017-08-29 |
2020-07-08 |
Amgen Inc |
Composés macrocycliques permettant d'inhiber la protéine mcl-1
|
|
EP3762393B1
(en)
|
2018-03-05 |
2023-01-11 |
Amgen Inc. |
Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists
|
|
JP6899975B2
(ja)
|
2018-05-14 |
2021-07-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｍｃｌ−１阻害剤
|
|
EP3877390A1
(en)
*
|
2018-11-09 |
2021-09-15 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
WO2020147802A1
(en)
*
|
2019-01-18 |
2020-07-23 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Macrocyclic spiroethers as mcl-1 inhibitors
|
|
AU2020279979A1
(en)
|
2019-05-20 |
2021-11-25 |
Les Laboratoires Servier |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
MA56505A
(fr)
*
|
2019-06-21 |
2022-04-27 |
Janssen Pharmaceutica Nv |
Inhibiteurs macrocycliques de mcl-1
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
KR20220034136A
(ko)
|
2019-07-09 |
2022-03-17 |
얀센 파마슈티카 엔.브이. |
Mcl-1 억제제로서의 거대환식 스피로사이클 유도체
|
|
EP3771469A1
(en)
*
|
2019-07-30 |
2021-02-03 |
Amgen, Inc |
Formulations and dosages for administering a compound that inhibits mcl1 protein
|
|
WO2021047616A1
(zh)
*
|
2019-09-12 |
2021-03-18 |
苏州亚盛药业有限公司 |
氧氮杂环庚烷类螺环化合物、中间体及其制备方法
|
|
PH12022550835A1
(en)
|
2019-10-18 |
2023-07-03 |
Forty Seven Inc |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
CN121471132A
(zh)
*
|
2019-11-04 |
2026-02-06 |
锐新医药公司 |
Ras抑制剂
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
CA3294692A1
(en)
*
|
2019-11-26 |
2026-03-02 |
Gilead Sciences, Inc. |
Processes and intermediates for preparing mcl1 inhibitors
|
|
CN115362003B
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
CN115151551B
(zh)
*
|
2020-02-21 |
2024-10-25 |
詹森药业有限公司 |
作为mcl-1抑制剂的大环吲哚衍生物
|
|
JP7873057B2
(ja)
*
|
2020-03-31 |
2026-06-11 |
アムジエン・インコーポレーテツド |
Ｍｃｌ－１化合物のメチル化
|
|
US20230212191A1
(en)
*
|
2020-04-16 |
2023-07-06 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
|
JP7564888B2
(ja)
|
2020-05-01 |
2024-10-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
|
|
CA3180566A1
(en)
*
|
2020-05-06 |
2021-11-11 |
Amgen Inc. |
Synthesis of sulfonamide intermediates
|
|
TWI827924B
(zh)
|
2020-05-06 |
2024-01-01 |
美商安進公司 |
大環Mcl-1抑制劑中間體的閉環合成
|
|
ES3038201T3
(en)
*
|
2020-05-06 |
2025-10-10 |
Amgen Inc |
Synthesis of vinylic protected alcohol intermediates
|
|
MX2022013872A
(es)
*
|
2020-05-06 |
2022-11-30 |
Amgen Inc |
Sintesis de productos intermedios de alcohol vinilico.
|
|
TWI867217B
(zh)
*
|
2020-05-06 |
2024-12-21 |
美商安進公司 |
乙烯基環丁基中間體之合成
|
|
KR20230023008A
(ko)
*
|
2020-06-10 |
2023-02-16 |
얀센 파마슈티카 엔.브이. |
Mcl-1의 억제제로서의 마크로사이클릭 2-아미노-3-플루오로-부트-3-엔아미드
|
|
JP7825954B2
(ja)
|
2020-08-26 |
2026-03-09 |
アムジエン・インコーポレーテツド |
Ｍｃｌ－１阻害剤処方物
|
|
US12552808B2
(en)
|
2020-09-03 |
2026-02-17 |
Amgen Inc. |
Diol desymmetrization by nucleophilic aromatic substitution
|
|
IL301298A
(en)
|
2020-09-15 |
2023-05-01 |
Revolution Medicines Inc |
Indole derivatives as RAS inhibitors in cancer therapy
|
|
US12202782B2
(en)
*
|
2020-11-19 |
2025-01-21 |
Gilead Sciences, Inc. |
Processes and intermediates for preparing MCL1 inhibitors
|
|
JP2023553808A
(ja)
|
2020-11-24 |
2023-12-26 |
ノバルティス アーゲー |
Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
|
|
KR20230113577A
(ko)
*
|
2020-11-25 |
2023-07-31 |
암젠 인크 |
알데히드의 거울상이성질체 선택적 알케닐화
|
|
EP4255409A1
(en)
|
2020-12-07 |
2023-10-11 |
Cellestia Biotech AG |
Pharmaceutical combinations for treating cancer
|
|
EP4008324A1
(en)
|
2020-12-07 |
2022-06-08 |
Cellestia Biotech AG |
Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
|
|
EP4263558B1
(en)
|
2020-12-17 |
2025-02-12 |
JANSSEN Pharmaceutica NV |
Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
US20240239812A1
(en)
|
2021-04-26 |
2024-07-18 |
Janssen Pharmaceutica Nv |
Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1
|
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
JP7900421B2
(ja)
|
2021-06-11 |
2026-08-04 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
|
|
TWI861509B
(zh)
|
2021-06-11 |
2024-11-11 |
美商基利科學股份有限公司 |
Mcl-1抑制劑與抗體藥物接合物之組合
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
EP4423078A1
(en)
|
2021-10-28 |
2024-09-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
KR20240107105A
(ko)
|
2021-11-16 |
2024-07-08 |
얀센 파마슈티카 엔브이 |
Mcl-1의 억제제로서의 매크로사이클릭 2-아미노-부트-3-엔아미드
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN118488948A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
CA3248911A1
(en)
|
2022-01-28 |
2023-08-03 |
Gilead Sciences, Inc. |
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
|
|
PL4245756T3
(pl)
|
2022-03-17 |
2025-02-17 |
Gilead Sciences, Inc. |
Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
WO2023196361A1
(en)
|
2022-04-05 |
2023-10-12 |
Amgen Inc. |
Amorphous and crystalline forms of mci-1 antagonists
|
|
US12351588B2
(en)
|
2022-04-05 |
2025-07-08 |
Amgen Inc. |
Salt forms and solvates of Mcl-1 antagonists
|
|
EP4511127A1
(en)
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
IL317101A
(en)
|
2022-05-20 |
2025-01-01 |
Novartis Ag |
Antibody-drug conjugates of anticancer compounds and methods of using them
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
JP2026522894A
(ja)
|
2023-06-30 |
2026-07-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｋｒａｓ調節化合物
|
|
CN121568935A
(zh)
|
2023-07-26 |
2026-02-24 |
吉利德科学公司 |
Parp7抑制剂
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
EP4516807A1
(en)
|
2023-08-28 |
2025-03-05 |
Consorcio Centro de Investigación Biomédica en Red |
Compositions for use in a method of providing improved hematopoietic stem cell engraftment
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
EP4774280A1
(en)
|
2023-09-08 |
2026-07-15 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
UY40985A
(es)
|
2023-11-22 |
2025-06-30 |
Servier Lab |
Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
|
|
AR134424A1
(es)
|
2023-11-22 |
2026-01-14 |
Novartis Ag |
Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20260130893A1
(en)
|
2024-10-21 |
2026-05-14 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026136515A1
(en)
|
2024-12-19 |
2026-06-25 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|